RAS Amplification as a Negative Predictor of Benefit from Anti‐EGFR–Containing Therapy Regimens in Metastatic Colorectal Cancer

BACKGROUND: RAS short variant (SV) mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR) monoclonal antibody (EGFRmAb). However, the clinical implications for RAS amplification (RASa) as a biomarker for anti‐EGFR therapy in CRC remain i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Schrock, Alexa B., Lee, Jessica K., Sandhu, Jaideep, Madison, Russell, Cho‐Phan, Cheryl, Snider, Jeremy W., Castellanos, Emily, Venstrom, Jeffrey M., Fakih, Marwan
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2021
Schlagworte:
Gastrointestinal Cancer
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176984/
https://ncbi.nlm.nih.gov/pubmed/33465286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13679
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge